Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 15/20 | 0.56 |
| ▸ | XIAP | P98170 | 12/20 | 0.54 |
| ▸ | BIRC3 | Q13489 | 9/20 | 0.54 |
| ▸ | BIRC7 | Q96CA5 | 2/20 | 0.52 |
| ▸ | CASP9 | P55211 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10081350 | 1.00 | BIRC2 (0.56) | BIRC2XIAPBIRC3BIRC7CASP9 | |
| SCHEMBL12130787 | 1.00 | BIRC2 (0.56) | BIRC2XIAPBIRC3BIRC7CASP9 | |
| SCHEMBL13181397 | 0.96 | BIRC2 (0.58) | BIRC2XIAPBIRC3BIRC7CASP9 | |
| SCHEMBL12133502 | 0.96 | BIRC2 (0.58) | BIRC2XIAPBIRC3BIRC7CASP9 | |
| SCHEMBL14267176 | 0.96 | BIRC2 (0.52) | BIRC2XIAPBIRC3BIRC7 | |
| SCHEMBL13790746 | 0.94 | BIRC2 (0.51) | BIRC2XIAPBIRC3BIRC7CASP9 | |
| SCHEMBL13693944 | 0.92 | BIRC2 (0.61) | BIRC2XIAPBIRC3BIRC7CASP9 | |
| SCHEMBL13119699 | 0.92 | BIRC2 (0.57) | BIRC2XIAPBIRC3BIRC7CASP9 | |
| SCHEMBL13154301 | 0.92 | BIRC2 (0.65) | BIRC2XIAPBIRC3BIRC7CASP9 | |
| SCHEMBL12130789 | 0.92 | BIRC2 (0.65) | BIRC2XIAPBIRC3BIRC7CASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589118-B2 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. | 2009-09-15 | — | — | US | disclosed |
| US-7589118-B2 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. | 2009-09-15 | — | — | US | disclosed |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | BAD, BIRC5, BAX | BIRC2 7/4885XIAP 6/4885BIRC3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.